Join HSANZ
On behalf of HSANZ President Leanne Berkahn and Vice President Steven Lane, this note is being shared from THANZ.
Dear colleagues,
Amidst the community concerns regarding COVID and COVID vaccination, some of us have noted cases of thrombocytopenia following COVID vaccination. Although immune thrombocytopenia (ITP) has been described in the medical literature following mRNA vaccines (Pfizer), we are now accumulating local experience with this phenomenon after AstraZeneca vaccination.
We are now LIVE with an online HREC approved REDCap registry to collect de-identified data on the presentation and clinical outcome of cases that you believe may represent an immune thrombocytopenia (Vaccine Induced ITP) following any COVID vaccination (Pfizer, AstraZeneca, etc). Some of these cases may occur as a relapse in patients with a prior history of ITP. Many cases may be de novo. Some patients may even share features with VITT/TTS (Vaccine Induced Immune Thrombosis and Thrombocytopenia). We would like to collect information on any of these presentations.
Please do not hesitate to contact us directly
Phil Choi ; Robert Bird or via THANZ with any queries. The link below requires no special software, and can be accessed and answered from your mobile device. So far it has taken clinicians less than 5 minutes to complete! All contributions will be acknowledged in any publications ensuing.
https://smex12-5-en-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fredcap.link%2fVIITP%5fAUS&umid=9dee37cb-4816-4faa-babd-b746a64f2e1e&auth=bb7c7bbf7acee6ae97e29073e34f3e8b1808c238-6849cb76fb7f27edfd6b1c21ac7928afb95f09f2
Dr Phil Choi (ACT) and Professor Robert Bird (Qld)
On behalf of the THANZ Vaccine Induced Immune Thrombocytopenia Working Group, and ISTH Platelet Immunology Subcommittee
Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination
Updated 24 May 2021 10:00 AM
Leanne Berkahn and Steven Lane, on behalf of the HSANZ Council.
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination. This is a dynamic topic and the clinical data are still emerging. HSANZ does not provide comment on specific cases, particularly without access to all of the information. However, we acknowledge that there is an important role in facilitating communication on this topic.
The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/ resources come to hand.
The Thrombosis Society of Australia and New Zealand have released some local guidelines. The following link provides information about the diagnosis and management of VIPIT and also a link to the referral form for testing of suspected cases.
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 24 May 2021
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The fourth webinar of the series features A/Prof Luca Vago, who is the Group Leader of the Unit of Immunogenetics, Leukaemia Genomics and Immunobiology at the Vita-Salute San Raffaele University in Milano. In his talk, A/Prof Vago will be outlining recent advances in the understanding of the mechanisms of post-HSCT relapse.
Speaker:
Associate Professor Luca Vago - San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milano
When: Monday 24 May 2021, 5pm AEST
Link to webinar:
Link to CBTCT website for all webinar recordings:
Brochure for webinar
from Leanne Berkahn (President), Steven Lane (Vice President), on behalf of the HSANZ Council and Nada Hamad, HSANZ Member.
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination. This is a rapidly evolving field and the clinical data are still emerging. HSANZ aims to facilitate dissemination of information as it becomes available.
The HSANZ will not comment on individual cases however, the following resources may be useful in supporting clinicians and patients. The content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/resources emerge.
2nd April 2021 TGA Media Release: Specific Clotting Condition reported after COVID-19 Vaccination 2nd April 2021 ATAGI media release: ATAGI statement on COVID-19 vaccination and a reported case of thrombosisCOVID-19 Advisory for Ontario Canada VIPIT Guidance
British Society of Haematology VIPIT Guidance
German Thrombosis and Haemostasis Society VIPIT Guidance
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT in Australia and New Zealand. For the full statement please go to the HSANZ Members only site.
Date of preparation: 6 April, 2021
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination.
The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ.
https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT.
For the full statement please go to the HSANZ Members only site
The Kanematsu Research Award is made annually by the Kanematsu Fund in memory of its founder Fusajiro Kanematsu and his wife Sen. The award is made for a single medical research project in the area of haematological disorders.
All information is available on the RCPA website with more information here
Closing date: 30 June 2021
For any questions, contact Eve Propper
The webinar is about Zainab’s Story and the international effort to find rare blood to save this young girl’s life.
The webinar will be presented by a host of presenters from the USA beginning with Dr Richard Gammon and includes Nancy Benitez (OneBlood USA), Sandra Nance (Rare Donor Program American Red Cross) and Tanya Powley (Australian Red Cross Lifeblood) as they share how they searched the world to find compatible blood for Zainab, a two-year-old girl with a rare blood group.
There will be opportunity for a live Q&A from the audience with all the presenters at the end of the presentation.
When: 8:00am AEDT Tuesday 30 March 2021
To register: Visit ANZSBT website and click on the link
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The second webinar of 2021 features Assistant Professor Saar Gill from the University of Pennsylvania, whose research laboratory currently focuses on the interface between adoptive cellular therapy and genetic engineering, and he is currently leading several clinical trials of CAR T cells for chronic and acute leukaemia. In this webinar, A/Prof Gill will provide valuable insights into the developments being made in role of CAR T cells for the treatment of myeloid malignancies.
A/Professor Saar Gill – Perelman School of Medicine, University of Pennsylvania
When: Monday 22 March 2021, 8am AEDT
For more formation - link
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 15 March 2021
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The first webinar of 2021 features presentations of two emerging areas of interest in the allogeneic stem cell transplantation field, with Prof David Gottlieb outlining the potential of adoptive T cell therapies for the treatment of invasive fungal infections following allogeneic stem cell transplantation and Dr Abir Bhattacharyya outlining approaches to managing donor specific antibodies in the context of haploidentical stem cell transplantation.
Speakers:
Professor David Gottlieb – Westmead Hospital and the University of Sydney
Dr Abir Bhattacharyya – Westmead Hospital
When: Monday 15 March 2021, 12pm AEDT
For more information click here
The 2021 Highlights of ASH has officially commenced!
This year’s all-virtual experience will take place between March 1 and April 2 and will feature curated annual meeting content that is relevant to all regions in which ASH has historically presented, including North America, the Mediterranean, Asia-Pacific, and Latin America. Attendees will receive full access to the entire program and content on the virtual platform until April 2, including:
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.
Privacy Policy
